Behind the Science
Advancing the search for more targeted cancer treatment
In the quest to outsmart cancer, teams at GSK are researching multiple technologies, including antibody-drug conjugates (ADCs). In this article, leading experts explain the science behind this growing field of oncology.
Who we are
As a focused biopharma company, we discover, develop and deliver medicines and vaccines to create value for patients and shareholders. We aim to positively impact the health of 2.5 billion people by the end of the decade.Our R&D focus is on four therapeutic areas: respiratory, immunology and inflammation; oncology; HIV; and infectious diseases.
Behind the Science
